Check out this study authored by several researchers, including Dr. Stefan Gravenstein who recently presented at an AVAC briefing on Capitol Hill. The study is entitled Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine in a Long-Term Care Population During an A/H1N1-Predominant Influenza Season. The study found that the use of HD influenza vaccine in long-stay NH residents reduced total health care expenditures for a net benefit despite HD being more expensive per dose. These cost offsets applied to Medicare beneficiaries residing in NHs could result in important savings to the Medicare program.